EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy

Shaoxing Guan, Guosheng Yuan, Tu Xian, Yongru Chen, Ruitong Li, Gengyi Zhang, Sumyuet Chan, Jian-Hong Fang, Min Huang, Huichang Bi, Jinzhang Chen

Drug Metabolism and Disposition · 2025-12 · 53 (12) · 100192

DOI: 10.1016/j.dmd.2025.100192 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Drug Metabolism and Disposition, 2025-12. Verfasst von Shaoxing Guan und 10 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-M…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immune Checkpoint Inhibitors, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Program, National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although tyrosine kinase inhibitor and immune checkpoint inhibitor (TKI-ICI) combination therapy has emerged as a promising treatment for hepatocellular carcinoma (HCC), reliable biomarkers for predicting long-term survival remain underexplored. Here, we conducted metabolomics and lipidomics profiling in baseline plasma samples from 58 patients with HCC who received TKI-ICI therapy in a prospective phase II trial. Prognostic features were identified using an integrated machine learning framework combining random forest survival analysis, LASSO regression, and Cox modeling. Untargeted metabolomics identified 2 lipids, phosphatidylinositol lyso 18:1 and O-phosphorylethanolamine, that were associated with progression-free survival. Lipidomics further revealed 9 prognostic lipids, including cholesteryl ester (18:1), triacylglycerol (TG) (15:0/15:0/21:6), TG (18:1/20:5/20:5), TG (41:3), phosphatidylserine (42:3), phosphatidylethanolamine (38:5), sphingosine (d18:1), phosphatidylcholine (43:5), and ceramide (d18:2/22:0), as independent predictors of progression-free survival. Multivariate Cox modeling integrating metabolomic and lipidomic markers reinforced their prognostic relevance. Meanwhile, 6 lipids, including phosphatidylcholine (39:8p), phosphatidylserine (18:0/20:4), TG (18:1/20:4/22:5), TG (15:0/15:0/21:6), ph sphingomyelin (d38:5), and sphingomyelin (d41:5), were found to be associated with overall survival. Functional enrichment analysis revealed that these prognostic lipids were involved in sphingolipid-related metabolism and immune-related signaling, highlighting the importance of lipid-immune crosstalk in reshaping responses to TKI-ICI therapy in patients with HCC. As sphingolipids are also known to modulate drug metabolism enzymes and transporters, they may thereby affect interindividual variability in TKI pharmacokinetics. In conclusion, our findings demonstrated that circulating lipidomic features, particularly sphingolipid-related species, were predictive of long-term survival in patients with HCC receiving TKI-ICI combination therapy. These lipids may serve as noninvasive biomarkers for survival prediction, patient stratification, and informed therapeutic decision making, while offering insights into lipid-immune interplay in immunotherapy-based cancer treatment. SIGNIFICANCE STATEMENT: This study integrates metabolomic and lipidomic profiling of baseline plasma from patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy, identifying sphingolipid-related lipid species as strong predictors of long-term survival. Unlike prior work focused on short-term response or monotherapy, these findings highlight lipidomic markers as noninvasive tools for survival prediction and treatment stratification, providing new insights into lipid-immune interactions and supporting the clinical utility of lipidomic signatures in guiding therapeutic decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmune Checkpoint InhibitorsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansLipidomicsMaleFemaleMiddle AgedMetabolomicsAgedProspective StudiesPrognosisBiomarkers, TumorAdultTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Hepatocellular carcinomaImmune checkpoint inhibitorLipidomicsMetabolomicsSphingolipidsTyrosine kinase inhibitor

Substanzen

Immune Checkpoint InhibitorsProtein Kinase InhibitorsBiomarkers, TumorTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…
  • State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
  • State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electr…

Förderung

  • Shenzhen Science and Technology Innovation Program
  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Guan, S., Yuan, G., Xian, T., Chen, Y., Li, R., Zhang, G., Chan, S., Fang, J. H., Huang, M., Bi, H., & Chen, J. (2025). Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy. Drug Metabolism and Disposition, 53(12), 100192. https://doi.org/10.1016/j.dmd.2025.100192

Vancouver

Guan S, Yuan G, Xian T, Chen Y, Li R, Zhang G, et al. Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy. Drug Metabolism and Disposition. 2025;53(12):100192. doi:10.1016/j.dmd.2025.100192

BibTeX
@article{Guan2025,
  author = {Guan, Shaoxing and Yuan, Guosheng and Xian, Tu and Chen, Yongru and Li, Ruitong and Zhang, Gengyi and Chan, Sumyuet and Fang, Jian-Hong and Huang, Min and Bi, Huichang and Chen, Jinzhang},
  title = {Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  volume = {53},
  number = {12},
  pages = {100192},
  doi = {10.1016/j.dmd.2025.100192}
}
Kostenlos starten →